Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment
NCT01613690
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Impairment
Interventions
DRUG:
NVA237
Sponsor
Novartis Pharmaceuticals